CSIMarket Company Name, Ticker, Industry, else..
 
Ocular Therapeutix Inc   (NASDAQ: OCUL)
 

Ocular Therapeutix Inc's Suppliers Performance

OCUL's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
OCUL Costs vs Sales of Suppliers Growth Ocular Therapeutix Inc recorded an increase in cost of sales by 3.45 % year on year, sequentially cost of sales grew by 51.32 % in Q2.

• More on OCUL Suppliers



Ocular Therapeutix Inc recorded increase in cost of sales by 3.45 % year on year, sequentially cost of sales grew by 51.32 % in Q2.

• More on OCUL Suppliers




Ocular Therapeutix Inc's Comment on Supply Chain


The company procures raw materials and components for injector and hydrogel platform manufacturing from multiple vendors on a purchase order basis, typically sole-sourcing each component. Vendors are qualified according to the company's quality system requirements. There are no long-term supply agreements or technology licenses with raw material or drug substance vendors. The company maintains strategic manufacturing capabilities that support rapid product development, flexibility, and quality control, with fully integrated manufacturing processes and project teams. Sterilization and packaging services are outsourced. The company intends to continue commercial manufacturing to support DEXTENZA sales and supply clinical materials for AXPAXLI and other product candidates, including scaling up manufacturing for potential commercialization of AXPAXLI.

Ocular Therapeutix Inc's Comment on Supply Chain


The company procures raw materials and components for injector and hydrogel platform manufacturing from multiple vendors on a purchase order basis, typically sole-sourcing each component. Vendors are qualified according to the company's quality system requirements. There are no long-term supply agreements or technology licenses with raw material or drug substance vendors. The company maintains strategic manufacturing capabilities that support rapid product development, flexibility, and quality control, with fully integrated manufacturing processes and project teams. Sterilization and packaging services are outsourced. The company intends to continue commercial manufacturing to support DEXTENZA sales and supply clinical materials for AXPAXLI and other product candidates, including scaling up manufacturing for potential commercialization of AXPAXLI.







OCUL's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Ocular Therapeutix Inc 2,332.91 52.05 -301.45 325
SUBTOTAL 0.00 0.00 0.00 -


Sources: Ocular Therapeutix Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Ocular Therapeutix Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.